Fluorocyclopentenylcytosine

Drug Profile

Fluorocyclopentenylcytosine

Alternative Names: FCPEC; RX 3117

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Apoptosis stimulants; CDC2 protein kinase inhibitors; Cell division inhibitors; DNA cytosine 5 methyltransferase 1 inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Bladder cancer
  • Phase I Solid tumours

Most Recent Events

  • 31 Oct 2016 Rexahn Pharmaceuticals receives patent allowance for fluorocyclopentenylcytosine in the US in October 2016
  • 07 Oct 2016 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 13 Sep 2016 Phase-II clinical trials in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (9206481; 9202965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top